Australia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.03-1.01 (-5.60%)
At close: 04:00PM EST
16.95 -0.08 (-0.47%)
After hours: 07:31PM EST
Full screen
Trade prices are not sourced from all markets
Previous close18.04
Open18.08
Bid17.03 x 800
Ask17.05 x 1300
Day's range16.70 - 18.17
52-week range4.51 - 31.50
Volume928,847
Avg. volume814,833
Market cap1.295B
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-0.54
Earnings date09 Feb 2022 - 14 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est38.29
  • Motley Fool

    Anavex Life Sciences (AVXL) Q4 2021 Earnings Call Transcript

    With us today is Dr. Christopher Missling, president and chief executive officer; and Sandra Boenisch, principal financial officer. Following management's remarks, there will be a question-and-answer session.

  • GlobeNewswire

    Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

    NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to partic

  • GlobeNewswire

    Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results

    Webcast and Conference Call Today at 4:30 p.m. Eastern TimeNEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ende